A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug.

John L Wallace Peter NagyTroy D FeenerThibault AllainTamás DitróiDavid J VaughanMarcelo Nicolas MuscaráGilberto de NucciAndre G Buret

Published in: British journal of pharmacology (2019)

This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc.

Keyphrases

clinical trial
anti inflammatory
benign prostatic hyperplasia
lower urinary tract symptoms
phase ii
study protocol
randomized controlled trial
emergency department
double blind
phase iii